Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE1
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Imetelstat Combinations in Relapsed AML
- Status
- RECRUITING
- Phase
- PHASE1
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
- Status
- RECRUITING
- Phase
- PHASE2
Ascorbate in Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE1
Pilot Study of Reduced Venetoclax Exposure
- Status
- RECRUITING
- Phase
- PHASE2
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
- Status
- RECRUITING
- Phase
- PHASE2
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
- Status
- RECRUITING
- Phase
- PHASE3
MRD-positive AML Clinical Study
- Status
- RECRUITING
- Phase
- NA
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
- Status
- RECRUITING
- Phase
- PHASE4
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- Status
- RECRUITING
- Phase
- PHASE2
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2